Eyestem, a 14-member biotech startup from Bengaluru is turning heads in global pharma circles. With just $10 million and a modest 1,200 sq ft office, it has developed a promising cell therapy for dry age-related macular degeneration (AMD)—a condition that leads to blindness and has no cure. Early trial results are not only encouraging, they’re outperforming billion-dollar competitors in the West.
But this isn’t just about scientific innovation. It’s about doing more with less. Eyestem’s founders set out with a bold goal: to build a cutting-edge treatment that’s actually affordable, especially for Indian patients. Think world-class therapy in under $10,000. In the current world of cell and gene therapies, where treatments often cost hundreds of thousands of dollars and remain out of reach for most, it is next to impossible.
How did Eyestem achieve this and what does this means for the future of biotech in India?
Tune in.
If you have any thoughts or questions about this episode, send them to us as texts or voice notes on Daybreak’s WhatsApp at +918971108379.
Daybreak is produced from the newsroom of The Ken, India’s first subscriber-only business news platform. Subscribe for more exclusive, deeply-reported, and analytical business stories.
